Neuromuscular blocking drugs in pediatric anesthesia

Anesthesiology Clinics of North America

Volumn 20, Issue 1, 2002, Pages 45-58

  Brandom, Barbara W ^a   Fine, Gavin F ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; CISATRACURIUM; DOXACURIUM; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; RAPACURONIUM BROMIDE; ROCURONIUM; SUXAMETHONIUM; VECURONIUM;

AGE; ANAPHYLAXIS; BRONCHOSPASM; DRUG POTENCY; EVALUATION; HUMAN; HYPERKALEMIA; INTENSIVE CARE; LARYNX SPASM; MUSCLE ATROPHY; PEDIATRIC ANESTHESIA; REVIEW;

EID: 0036200870     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8537(03)00054-3     Document Type: Review

References (59)

1. Clinical pharmacokinetics of the newer neuromuscular blocking drugs
2. Neuromuscular effects of rapacuronium in pediatric patients during nitrous oxide-halothane anesthesia: Comparison with mivacurium
3. Spontaneous versus edrophonium-induced recovery from paralysis with mivacurium
4. Recovery from doxacurium infusion administered to produce immobility for more than four days in pediatric patients in the intensive care unit
5. Recovery from cisatracurium given after days of doxacurium infusion in the pediatric intensive care unit
6. Persistent anaphylactic reaction after induction with thiopentone and cisatracurium
7. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound vecuronium in human volunteers
8. Is intramuscular mivacurium an alternative to intramuscular succinylcholine?
9. The prolonged duration of rocuronium in Chinese patients
10. The time-course of action and recovery from rocuronium 0.3 mg/kg in infants and children during halothane anaesthesia measured with acceleromyography
11. Unmasked residual neuromuscular block after administration of vecuronium for days
12. Increases in airway resistance in children: Comparison between rapacuronium and mivacurium
13. Pharmacokinetics and pharmacodynamics of atracurium in infants and children
14. Rapacuronium administration to two children with Duchenne's muscular dystrophy
15. The changing pharmacodynamics of metocurine identify the onset and offset of canine gastrocnemius disuse atrophy
16. Rapacuronium and bronchospasm
17. Cardiac arrest after succinylcholine: Mortality greater with rhabdomyolysis than receptor upregulation
18. Antagonism of intense atracurium-induced neuromuscular block in children
19. Jaw relaxation after a halothane/succinylcholine sequence in children
20. Tolerance and upregulation of acetylcholine receptors follows chronic infusions of d-tubocurarine
21. Laboratory investigations-neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors
22. The influence of the duration of isoflurane anaesthesia on neuromuscular effects of mivacurium
23. Isolated masseter spasm and increased serum creatine kinase without malignant hyperthermia susceptibility or other myopathies
24. The potency (ED50) and cardiovascular effects of rapacuronium (Org 9487) during narcotic-nitrous oxide propofol anesthesia in neonates, infants, and children
25. Intramuscular rocuronium in infants and children: A multicenter study to evaluate tracheal intubating conditions, onset and duration of action
26. The pharmacokinetics and steady-state pharmacodynamics of mivacurium in children
27. Hyperkalemic cardiac arrest after succinylcholine administration in a child with purpura fulminans
28. Severe bronchospasm and desaturation in a child associated with rapacuronium
29. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies
30. Epidemiology of anesthetic anaphylactoid reactions. Fourth multicenter survey (July 1994-December 1996)
31. Severe anaphylactic reaction to cisatracurium in a child
32. The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia
33. Masseter muscle spasm in children: Implications of continuing the anesthetic
34. Mivacurium or vecuronium for paediatric ENT surgery. Clinical experience and cost analysis
35. Neuromuscular effects of mivacurium in 2 to 12-year-old children with burn injury
36. A dose-ranging study of rapacuronium in pediatric patients
37. Bronchospasm after rapacuronium in infants and children
38. Is vecuronium a long-acting neuromuscular blocking agent in neonates and infants?
39. Time course of potentiation of mivacurium by halothane and isoflurane in children
40. Agreement between muscle movement and peripheral nerve stimulation in critically ill pediatric patients receiving neuromuscular blocking agents
41. Comparative pharmacology of succinylcholine on jaw, eye, and tibialis muscle
42. Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration
43. Intramuscular rocuronium in infants and children. Dose-ranging and tracheal intubating conditions
44. Comparison of time course of neuromuscular blockade in young children following rocuronium and atracurium
45. Rocuronium: High risk for anaphylaxis?
46. Clinical pharmacology of mivacurium chloride (BW 1090U) in children during nitrous oxide-halothane and nitrous oxide narcotic anesthesia
47. Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children
48. Pharmacodynamics of high-dose vecuronium in children during balanced anesthesia
49. Halothane and temperature interact to increase succinylcholine-induced jaw contracture in the rat
50. The safety and efficacy of cisatracurium 0.15 mg/kg during nitrous oxide-opioid anaesthesia in infants and children
51. Rocuronium in infants, children, and adults during balanced anaesthesia
52. Neuromuscular junction in cerebral palsy, presence of extra-junctional acetylcholine receptors
53. Continuous infusion of rocuronium in a paediatric intensive care unit
54. Pancuronium infusion for neuromuscular block in children in the intensive care unit
55. Increased masticatory muscle stiffness during limb muscle flaccidity associated with succinylcholine administration
56. Cholinesterase in clinical medicine
57. Pharmacokinetics and pharmacodynamic modeling of rocuronium in infants and children
58. Neuromuscular effects of 600 mcg/kg of rocuronium in infants during nitrous oxide-halothane anesthesia
59. The influence of halothane, isoflurane and sevoflurane on rocuronium infusion in children